Oxford scientists detail real-world impact of coronavirus vaccination

26 April 2021

Large-scale research undertaken by the University of Oxford, published as two pre-prints, shows a significant fall in COVID-19 infections after a single vaccine dose.

Over the coming months, data from the studies could also be critical in helping public health authorities understand how much of an antibody response, over what time period, will offer long-term protection from the disease.

Conducted in collaboration with the UK’s Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), scientists looked at the impact of a single dose of either Vaxzevria, from AstraZeneca (LSE: AZN), or Comirnaty, from Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK